LV10190B - Method for treating alcoholism with nalmefene - Google Patents

Method for treating alcoholism with nalmefene Download PDF

Info

Publication number
LV10190B
LV10190B LVP-93-1052A LV931052A LV10190B LV 10190 B LV10190 B LV 10190B LV 931052 A LV931052 A LV 931052A LV 10190 B LV10190 B LV 10190B
Authority
LV
Latvia
Prior art keywords
alcohol
nalmefene
drinking
extinction
patient
Prior art date
Application number
LVP-93-1052A
Other languages
English (en)
Other versions
LV10190A (lv
Inventor
John D Sinclair
Scheinin Harry
Lammintausta Risto
Original Assignee
Alko Ltd
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alko Ltd, Orion Yhtymae Oy filed Critical Alko Ltd
Publication of LV10190A publication Critical patent/LV10190A/lv
Publication of LV10190B publication Critical patent/LV10190B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Claims (4)

  1. LV 10190 Patentformulas punkti 1. Nalmifīna pieliGtojums alkoholisma ārstēšanai ievadot to alkoholiķa organismā tādā dau- dzumā, kas pietiekošs alkohola stimulējošās darbības bloķēšanai, un dodot alkoholiķim dzert alkoholisku dzērienu, pie kam atkārtojot minētās darbības līdz tieksme pēc alkohola ir nomākta.
  2. 2. Pielietojums pēc punkta 1, kas atšķiras ar to, ka pacientu pēc alkoholiskā dzēriena iedzeršanas soda ar sodu no grupas: elektrošoks, vemšanas līdzekļu ievadīšana, sensibilizatora pret alkoholu ievadīšana.
  3. 3. Pielietojums pēc punkta 1, kas atšķiras ar to, ka nalmifīnu turpina ievadīt vēl pēc tam, kad nomākta tieksme pēc alkohola.
  4. 4. Pielietojums pēc punkta 1, kas atšķiras ar to, ka nalmifīna deva ir 0,1 - 300 mg dienā.
LVP-93-1052A 1990-06-04 1993-08-31 Method for treating alcoholism with nalmefene LV10190B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene
PCT/US1991/003241 WO1991018605A1 (en) 1990-06-04 1991-05-10 Method for treating alcoholism with nalmefene

Publications (2)

Publication Number Publication Date
LV10190A LV10190A (lv) 1994-10-20
LV10190B true LV10190B (en) 1995-06-20

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-1052A LV10190B (en) 1990-06-04 1993-08-31 Method for treating alcoholism with nalmefene

Country Status (19)

Country Link
US (1) US5086058A (lv)
EP (1) EP0531415B1 (lv)
JP (1) JP3059213B2 (lv)
AT (1) ATE145329T1 (lv)
AU (1) AU642748B2 (lv)
CA (1) CA2084519C (lv)
DE (1) DE69123247T2 (lv)
DK (1) DK0531415T3 (lv)
ES (1) ES2097209T3 (lv)
FI (1) FI925513A0 (lv)
GR (1) GR3022289T3 (lv)
HU (1) HU210637B (lv)
IE (1) IE77333B1 (lv)
LT (1) LT3893B (lv)
LV (1) LV10190B (lv)
NZ (1) NZ238391A (lv)
RU (1) RU2090190C1 (lv)
WO (1) WO1991018605A1 (lv)
ZA (1) ZA914185B (lv)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
SI1685839T1 (sl) 1997-12-22 2013-08-30 Euro-Celtique S.A. Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista
TR200001828T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
AU1807401A (en) * 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
NZ520554A (en) 2000-02-08 2005-08-26 Euro Celtique S Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
CN1273075C (zh) * 2001-07-13 2006-09-06 爱科来株式会社 分析用具、具备分析用具的浓度测定装置用的穿刺元件一体化安装体及体液采取用具
DK1416842T3 (da) * 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
DE60232417D1 (de) 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030153590A1 (en) * 2001-08-14 2003-08-14 Oy Contral Pharma Ltd Method of treating alcoholism or alcohol abuse
KR20040098050A (ko) 2002-04-05 2004-11-18 유로-셀띠끄 소시에떼 아노님 옥시코돈 및 날록손을 포함하는 약제학적 제제
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
WO2003101358A1 (en) * 2002-05-31 2003-12-11 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
PT1551372T (pt) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
DE602004031512D1 (de) 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
CA2522471A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8158156B2 (en) * 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
ES2618500T3 (es) 2006-10-20 2017-06-21 Neurendo Pharma, Llc Método para restaurar el efecto incretina
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
SI2307420T1 (sl) * 2008-04-24 2012-05-31 Janssen Pharmaceutica Nv Predzdravila nalmefen di estra
KR101598137B1 (ko) * 2008-04-24 2016-02-29 얀센 파마슈티카 엔.브이. 날메펜 프로드럭
CA2730211C (en) * 2008-07-07 2016-11-08 Euro-Celtique S.A. Use of opioid antagonists for treating urinary retention
EP2405915B1 (en) 2009-03-10 2018-10-24 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JP6419780B2 (ja) * 2013-04-17 2018-11-07 ハー・ルンドベック・アクチエゼルスカベット 睡眠障害患者の治療のためのナルメフェン
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
ES2742888T3 (es) * 2014-04-22 2020-02-17 Otsuka Pharma Co Ltd Combinación de brexpiprazol y nalmefeno y su uso para tratar trastornos relacionados con una sustancia
WO2016073615A1 (en) 2014-11-07 2016-05-12 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
KR20180129909A (ko) * 2016-04-22 2018-12-05 타이완제이 파마슈티컬스 컴퍼니 리미티드 (비)알콜성 지방간염 또는 비알콜성 지방간 질환의 치료에 사용하기 위한 날메펜, 날트렉손 또는 이의 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Also Published As

Publication number Publication date
WO1991018605A1 (en) 1991-12-12
AU7974091A (en) 1991-12-31
HU9203835D0 (en) 1993-03-29
FI925513A (fi) 1992-12-04
FI925513A0 (fi) 1992-12-04
AU642748B2 (en) 1993-10-28
DE69123247T2 (de) 1998-01-15
RU2090190C1 (ru) 1997-09-20
DE69123247D1 (de) 1997-01-02
LTIP1486A (en) 1995-09-25
US5086058A (en) 1992-02-04
ATE145329T1 (de) 1996-12-15
HU210637B (en) 1995-06-28
EP0531415A1 (en) 1993-03-17
IE911888A1 (en) 1991-12-04
JPH06506665A (ja) 1994-07-28
CA2084519A1 (en) 1991-12-05
LV10190A (lv) 1994-10-20
NZ238391A (en) 1997-06-24
ES2097209T3 (es) 1997-04-01
JP3059213B2 (ja) 2000-07-04
IE77333B1 (en) 1997-12-03
CA2084519C (en) 1999-02-09
DK0531415T3 (da) 1996-12-09
ZA914185B (en) 1992-07-29
HUT65523A (en) 1994-06-28
GR3022289T3 (en) 1997-04-30
EP0531415B1 (en) 1996-11-20
LT3893B (en) 1996-04-25

Similar Documents

Publication Publication Date Title
EP0531415B1 (en) Method for treating alcoholism with nalmefene
US4882335A (en) Method for treating alcohol-drinking response
Bem et al. Dextromethorphan: an overview of safety issues
Sandman The opiate hypothesis in autism and self-injury
Woolverton et al. The effects of a D1 and a D2 dopamine antagonist on behavior maintained by cocaine or food
Martin et al. Methadone—a reevaluation
Charney et al. Clonidine and naltrexone: a safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy
Stapleton et al. Naloxone reduces fluid consumption in water-deprived and nondeprived rats
EP1681057B1 (en) Use of naloxone for treating eating disorders
JPH11505547A (ja) ナルトレキソン及び関連化合物を用いる禁煙処置
EP0563336B1 (en) Pharmaceutical composition containing gamma-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders
DE112006001234T5 (de) Verfahren und Zusammensetzung zur Behandlung von ARG
Hubbell et al. Opioids modulate rats’ intakes of alcoholic beverages
Goetting et al. Systemic atropine administration during cardiac arrest does not cause fixed and dilated pupils
US5587381A (en) Method for terminating methadone maintenance through extinction of the opiate-taking responses
US5140032A (en) Drug therapy for alcohol abusers
EP3454853B1 (en) Treatment of alcoholism and depression using ibudilast
CA2429801A1 (en) Behavior chemotherapy
US5543407A (en) Preparation and application of scopolamine and chlorpromazine as a drug-withdrawal agent
Nagain‐Domaine et al. Modulation by alcohol and methadone of 2‐deoxyglucose‐stimulated pancreatic secretion in the rat
Cleary et al. Effects of imipramine on responding reduced by methadone
Reid et al. Research with rats germane to medication for alcoholism: Consequences of noncompliance
Doty et al. Effects of Naltrexone Pretreatment on Acute Responses to Ethanol in Social Drinkers
Hollandsworth et al. Psychoactive Substance Use Disorders